Received Jun 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Headache; fatigue; This non-serious case was reported by a consumer via call center representative and described the occurrence of headache in a male patient who received Herpes zoster (Shingrix) for prophylaxis. In OCT-2024, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced headache (Verbatim: Headache) and fatigue (Verbatim: fatigue). The outcome of the headache and fatigue were resolved. It was unknown if the reporter considered the headache and fatigue to be related to Shingrix. It was unknown if the company considered the headache and fatigue to be related to Shingrix. Additional Information: GSK Receipt Date: 12-JUN-2025 Patient received his first dose on 23rd or 24th October 2024. Patient had fatigue and a headache and stated that he does not remember how long it lasted after the first dose.; Sender's Comments: US-GSK-US2025073371:same patient